IFNA1 and neoplasm: Because IFN signalling in APCs drives antigen presentation and cross presentation to both CD8+ and CD4+ T cells (127), therapeutic administration of large doses of EVs loaded with STING agonist dinucleotides (exoSTING) is being explored to promote adaptive anti-tumor immune responses.